[go: up one dir, main page]

WO2006125555A3 - Chinazolinone - Google Patents

Chinazolinone Download PDF

Info

Publication number
WO2006125555A3
WO2006125555A3 PCT/EP2006/004655 EP2006004655W WO2006125555A3 WO 2006125555 A3 WO2006125555 A3 WO 2006125555A3 EP 2006004655 W EP2006004655 W EP 2006004655W WO 2006125555 A3 WO2006125555 A3 WO 2006125555A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinazolinones
compounds
tumors
things
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/004655
Other languages
English (en)
French (fr)
Other versions
WO2006125555A2 (de
Inventor
Hans-Peter Buchstaller
Dirk Finsinger
Kai Schiemann
Ulrich Emde
Frank Zenke
Christiane Amendt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/913,149 priority Critical patent/US20080234299A1/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to EP06753676A priority patent/EP1885702A2/de
Priority to CA002609391A priority patent/CA2609391A1/en
Priority to AU2006251355A priority patent/AU2006251355A1/en
Priority to JP2008512734A priority patent/JP2008542215A/ja
Publication of WO2006125555A2 publication Critical patent/WO2006125555A2/de
Publication of WO2006125555A3 publication Critical patent/WO2006125555A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Verbindungen der Formel (I), worin R, R1 , R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3, k und Y1 die in Anspruch 1 angegebenen Bedeutungen haben, können u.a. zur Behandlung von Tumoren eingesetzt werden.
PCT/EP2006/004655 2005-05-25 2006-05-17 Chinazolinone Ceased WO2006125555A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US11/913,149 US20080234299A1 (en) 2005-05-25 2006-03-17 Quinazolinones
EP06753676A EP1885702A2 (de) 2005-05-25 2006-05-17 Chinazolinone
CA002609391A CA2609391A1 (en) 2005-05-25 2006-05-17 Quinazolinones
AU2006251355A AU2006251355A1 (en) 2005-05-25 2006-05-17 Quinazolinones
JP2008512734A JP2008542215A (ja) 2005-05-25 2006-05-17 キナゾリノン

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005024017.8 2005-05-25
DE102005024017A DE102005024017A1 (de) 2005-05-25 2005-05-25 Chinazolinone

Publications (2)

Publication Number Publication Date
WO2006125555A2 WO2006125555A2 (de) 2006-11-30
WO2006125555A3 true WO2006125555A3 (de) 2007-05-18

Family

ID=36954835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004655 Ceased WO2006125555A2 (de) 2005-05-25 2006-05-17 Chinazolinone

Country Status (8)

Country Link
US (1) US20080234299A1 (de)
EP (1) EP1885702A2 (de)
JP (1) JP2008542215A (de)
AR (1) AR057322A1 (de)
AU (1) AU2006251355A1 (de)
CA (1) CA2609391A1 (de)
DE (1) DE102005024017A1 (de)
WO (1) WO2006125555A2 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214519B2 (en) 2016-09-23 2019-02-26 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10227350B2 (en) 2016-09-23 2019-03-12 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10479770B2 (en) 2016-09-23 2019-11-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537227T3 (es) 2010-10-01 2015-06-03 Applied Medical Resources Corporation Instrumento electro-quirúrgico con mordazas y con un electrodo
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013364068B2 (en) 2012-12-21 2016-10-20 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
US9029384B2 (en) 2012-12-21 2015-05-12 Gilead Calistoga, LLC. Phosphatidylinositol 3-kinase inhibitors
TWI644909B (zh) 2013-06-14 2018-12-21 基利科學股份有限公司 磷脂酸肌醇３－激酶抑制劑
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
EA201691872A1 (ru) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
MX391259B (es) 2015-10-14 2025-03-21 X Therma Inc Composiciones y métodos para reducir la formación de cristales de hielo.
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3322756A (en) * 1963-05-18 1967-05-30 Hoechst Ag 2-aminoalkyl-3-hydrocarbon quinazolones-(4)
WO2001098278A1 (en) * 2000-06-21 2001-12-27 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2002058684A2 (en) * 2000-11-06 2002-08-01 Combinatorx, Incorporated Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
WO2003035075A1 (en) * 2001-10-19 2003-05-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2003043961A2 (en) * 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3322756A (en) * 1963-05-18 1967-05-30 Hoechst Ag 2-aminoalkyl-3-hydrocarbon quinazolones-(4)
WO2001098278A1 (en) * 2000-06-21 2001-12-27 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2002058684A2 (en) * 2000-11-06 2002-08-01 Combinatorx, Incorporated Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
WO2003035075A1 (en) * 2001-10-19 2003-05-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2003043961A2 (en) * 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
AGER I R ET AL: "Synthesis and central nervous system activity of quinazolones related to 2-methyl-3-(o-tolyl)-4(3H)- quinazolone (methaqualone)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 20, no. 3, March 1977 (1977-03-01), pages 379 - 386, XP002156696, ISSN: 0022-2623 *
BERGMAN J ET AL: "SYNTHESIS OF CHRYSOGINE, A METABOLITE OF PENICILLIUM CHRYSOGENUM AND SOME RELATED 2-SUBSTITUTED 4-(3H)-QUINAZOLINONES", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 46, no. 4, January 1990 (1990-01-01), pages 1295 - 1310, XP002009812, ISSN: 0040-4020 *
BOLTZE K-H ET AL: "SUBSTITUIERTE CHINAZOLINONE-(4) ALS HYPNOTICA UND ANTIKONVULSIVA", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 13, no. 8, August 1963 (1963-08-01), pages 688 - 701, XP002064150, ISSN: 0004-4172 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1938, XP002400459 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1962, XP002400460 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1969, XP002400462 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1973, XP002400461 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1977, XP002400464 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1978, XP002400457 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1981, XP002400451 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1983, XP002400456 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1984, XP002400455 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1985, XP002400452 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1990, XP002400454 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1996, XP002400458 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1999, XP002400463 *
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 2001, XP002400453 *
HATTORI KOUJI ET AL: "Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase.", JOURNAL OF MEDICINAL CHEMISTRY. 12 AUG 2004, vol. 47, no. 17, 12 August 2004 (2004-08-12), pages 4151 - 4154, XP002399543, ISSN: 0022-2623 *
HUGHES L R ET AL: "QUINAZOLINE ANTIFOLATE THYMIDILATE SYNTHASE INHIBITORS: ALKYL, SUBSTITUTED ALKYL, AND ARYL SUBSTITUENTS IN THE C2 POSITION", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 33, no. 11, 1990, pages 3060 - 3067, XP002370288, ISSN: 0022-2623 *
IWASHITA AKINORI ET AL: "Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. JUN 2004, vol. 309, no. 3, June 2004 (2004-06-01), pages 1067 - 1078, XP002399542, ISSN: 0022-3565 *
JIANG J B ET AL: "Synthesis and Biological Evaluation of 2-Styrylquinazolin-4(3H)-ones, a new Class of Antimitotic Anticancer Agents Which Inhibit Tubulin Polymerisation", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 33, 1990, pages 1721 - 1728, XP002010826, ISSN: 0022-2623 *
O'MAHONY D J R ET AL: "Traceless synthesis of 3H-quinazolin-4-ones via a combination of solid-phase and solution methodologies", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 43, no. 6, 4 February 2002 (2002-02-04), pages 939 - 942, XP004333931, ISSN: 0040-4039 *
PARASHARYA P M ET AL: "4(3H)-quinazolones. Part I: 2-Alkyl/arylaminomethyl-3-p-hydroxy/metho xyphenyl-4(3H)-quinazolones", 1994, CHEMICAL ABSTRACTS + INDEXES, AMERICAN CHEMICAL SOCIETY. COLUMBUS, US, PAGE(S) 1065, ISSN: 0009-2258, XP002229326 *
WITT A ET AL: "Synthesis and Reactions of some 2-Vinyl-3H-quinazolin-4-ones", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 56, no. 37, 8 September 2000 (2000-09-08), pages 7245 - 7253, XP004211837, ISSN: 0040-4020 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214519B2 (en) 2016-09-23 2019-02-26 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10227350B2 (en) 2016-09-23 2019-03-12 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10479770B2 (en) 2016-09-23 2019-11-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
WO2006125555A2 (de) 2006-11-30
DE102005024017A1 (de) 2006-11-30
AR057322A1 (es) 2007-11-28
CA2609391A1 (en) 2006-11-30
AU2006251355A1 (en) 2006-11-30
JP2008542215A (ja) 2008-11-27
EP1885702A2 (de) 2008-02-13
US20080234299A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2007106192A3 (en) Inhibitors of iap
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
GB0305152D0 (en) Organic compounds
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2009046841A3 (de) Piperidin- und piperazinderivate zur behandlung von tumoren
WO2010038086A8 (en) P38 map kinase inhibitors
MX2007003470A (es) Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa.
TW200607806A (en) Pyrimidines as plk inhibitors
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
TW200801003A (en) Novel compounds
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2006125555A3 (de) Chinazolinone
MX2010003368A (es) Derivados de imidazol.
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
WO2006072615A3 (en) Triazolophthalazines as pde2-inhibitors
WO2007097981A3 (en) Alpha carbolines and uses thereof
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs
TW200630374A (en) Thiazolyldihydroindazoles
TW200635921A (en) Organic compounds
WO2006024640A3 (en) Triazolophthalazines
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
MX2008002104A (es) Derivados de 1-acildihidropirazol.
WO2007120333A3 (en) Tetracyclic kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006753676

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11913149

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2609391

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008512734

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006251355

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2006251355

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006251355

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006753676

Country of ref document: EP